However, no significant difference was observed for the risk of MACEs in Black patients (RR, 1.05; 95% CI: 0.72-1.53; <i>p</i> = 0.80) when comparing GLP-1 RAs with placebo.<h4>Conclusion</h4>This meta-analysis demonstrates that GLP-1 RAs significantly reduce the risk of MACEs in both males and females, as well as across various racial groups in patients with or without T2DM. Here, GLP1R is linked to type 2 diabetes mellitus.